相关实验视频

Updated: May 26, 2025

Pentylenetetrazole-Induced Kindling Mouse Model

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

在甲状腺激素载体Mct8/Oatp1c1淘汰赛小鼠中增加了发作易感性与改变的神经递质系统的发展有关

Andrea Alcaide Martin¹, Reinhard Bauer², Dagmar Führer-Sakel¹

¹University of Duisburg-Essen, University Hospital Essen, Dept. of Endocrinology, Diabetes and Metabolism, Essen, Germany; Center for Translational Neuro-, and Behavioral Sciences (C-TNBS), Medical Faculty, University of Duisburg-Essen, Essen, Germany.

Progress in neurobiology

|February 22, 2025

概括

甲状腺激素 (TH) 载体突变导致艾伦-赫伦登-达德利综合征 (AHDS),导致发作. 一个AHDS模型的Mct8/Oatp1c1双敲击小鼠,由于大脑神经递质系统的改变,其发作易感性增加.

科学领域:

神经科学是一个神经科学.
内分泌学在内分泌学.
遗传学是一个遗传学.

背景情况:

甲状腺激素 (TH) 运输体,如Mct8和Oatp1c1,对于TH运输到细胞中至关重要.
MCT8中的突变会导致艾伦-赫伦登-达德利综合征 (AHDS),其特征是精神运动迟缓,中央TH缺乏和发作.

研究的目的:

为了研究AHDS的小鼠模型中的发作易感性.
探索潜在的神经元和神经化学机制,有助于AHDS中发作.

主要方法:

使用Mct8/Oatp1c1双击 (Dko) 鼠标作为AHDS模型.
使用皮洛卡尔诱导的发作模型评估了发作易感性.
通过免疫光,ISH和qPCR分析了海马神经元变化 (cFos,索马托斯塔丁) 和神经递质系统 (GABAergic,Glutamatergic,Cholinergic).

主要成果:

Dko小鼠表现出显著增加的发作易感性和更快的发作状态 (SE).
河马分析显示,SE后CA3神经元中cFos免疫反活性和异位性索马托斯塔丁表达增加.
在Dko小鼠中观察到GABAergic,Glutamatergic和Cholinergic系统的异常发展.

结论:

在AHDS模型中,Mct8/Oatp1c1缺乏导致发作的易感性增加.
海马中关键神经递质系统的发育变化有助于增加发作风险.
研究结果表明,在Dko海马中抑制和激发之间的不平衡是病理的基础.

关键词:

对于GABA来说,这是一个很好的选择.谷氨酸酸盐的使用方法在海马体内,海马体皮洛卡尔类类植物.T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 在T4中,T4是T4.

更多相关视频

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse

Published on: October 6, 2023

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Arteries of the Lower Limbs

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...